Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. Class H (HK:6990) has released an update.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. has received approval from the China Securities Regulatory Commission to issue new domestic shares to a specific subscriber. This approval allows the company to proceed with the subscription under the specific mandate, marking a significant step in their financial strategy. The issuance will be conducted in accordance with regulatory requirements within the next 12 months.
For further insights into HK:6990 stock, check out TipRanks’ Stock Analysis page.